---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-24-000027"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T01:57:09.325841+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M

## Summary
- Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.
- Net income $306.6M ($6.17 diluted EPS) vs $240.9M ($4.86 EPS) in Q1 2023.
- Implemented $1B accelerated share repurchase with Citi; initial delivery of 3.275M shares.
- Tyvaso DPI sales $227.5M (+92% YoY); nebulized Tyvaso $145.0M (+21%).
- Revenue growth driven by increased patient utilization and Part D redesign tailwinds.

## SEC filing metadata
- accession: 0001082554-24-000027
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000027/0001082554-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000027/uthr-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-24-000027
- JSON: https://secwatch.observer/filing/0001082554-24-000027.json
- Plain text: https://secwatch.observer/filing/0001082554-24-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.